bosentan anhydrous has been researched along with Behcet Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daele, PLAV; Dik, WAV; Hagen, PMV; Houwen, TBV; Kappen, JH; Kuijpers, RWAM; Laar, JAMV | 1 |
1 trial(s) available for bosentan anhydrous and Behcet Syndrome
| Article | Year |
|---|---|
A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease.
Topics: Behcet Syndrome; Bosentan; Cytokines; Endothelial Cells; Humans; Pilot Projects; Prospective Studies | 2022 |